semaglutide creatinine Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT trial Weight loss medications are groundbreaking

2017 [cited 2019 Dec 23];31(9):37438

That is the role NAD Regen is designed to play

A GLP-1 receptor agonist refers to a class of medications used to treat type 2 diabetes and promote weight loss in adults and adolescents

These severe outcomes including significant loss of kidney function, kidney failure and death from kidney or cardiovascular causes occurred 331 times among trial participants who were treated with semaglutide, compared with 410 events among those who received the placebo

Patients with specific genetic profiles may tolerate schedule adjustments differently, which is why genetic insights inform your personalized treatment plan from the start